title: Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia.
abstract: Genomic markers are among the strongest prognostic factors in chronic lymphocytic leukemia (CLL). Chromosomal aberrations, IGHV and TP53 mutation status are well-established and essential to discriminate between a more indolent course of disease and a high-risk CLL, which requires an alternative treatment regimen. In addition, a variety of gene mutations with unclear prognostic value have been identified: SF3B1, ATM, and BIRC3 may describe CLL with adverse outcome, whereas NOTCH1 is predictive for resistance against CD20 antibodies. Integration of novel drivers into a small set of key pathways forms the basis for future pathogenetic and therapeutic implications.
authors.affiliation: Department of Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: Eugen
authors.initials: E
authors.lastname: Tausch
authors.forename: Daniel
authors.initials: D
authors.lastname: Mertens
authors.forename: Stephan
authors.initials: S
authors.lastname: Stilgenbauer
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D019317:Evidence-Based Medicine; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers; D009363:Neoplasm Proteins